跳至主要内容
临床试验/CTRI/2024/05/067023
CTRI/2024/05/067023尚未招募不适用

A retrospective, multicentre, observational, real-world post-market clinical follow-up study to evaluate the safety & effectiveness of Libertasâ„¢ Hip Replacement System is intended for use in total hip arthroplasty and hemi-hip arthroplasty

Meril Life Sciences Pvt Ltd3 个研究点 分布在 1 个国家目标入组 159 人开始时间: 2024年5月20日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
159
试验地点
3
主要终点
1. Mobility

研究概览

简要总结

Libertasâ„¢ Hip Replacement System PMCF Study: A retrospective, multicentre, observational, real-world post-market clinical follow-up study to evaluate the safety & effectiveness of Libertasâ„¢ Hip Replacement System isintended for use in total hip arthroplasty and hemi-hip arthroplasty

Protocol ID, Version & Date: MHPL/ Libertasâ„¢ Hip Replacement System PMCF Study Protocol_Version: 1.0.0_06-Dec-2023

Objective:: To evaluate the safety and performance of the Libertasâ„¢ Hip Replacement System intended for use in total hip arthroplasty and hemi-hip arthroplasty.

Study Design: A retrospective, multicenter, observational, real-world, postmarketclinical follow-up study.

Study population: All consecutive patients who underwent surgical intervention using Libertasâ„¢ Hip Replacement System and have a minimum of 2-year of follow-up completed.

Number of patients: 159 patients

Indication: The Libertas â„¢ Hip Replacement System is intended for use in total hip arthroplasty and hemi-hip arthroplasty. Total hip arthroplasty isintended to provide patient mobility and reduce pain by replacing the damaged hip joint articulation in patients where there is evidence of sufficient sound bone to fix and support the components. Hemi-hip arthroplasty is performed in patients where there is evidence of a satisfactory natural acetabulum and sufficient femoral bone to fix and support the femoral stem.

Total hip replacement is indicated for the following conditions:

  1. Non-inflammatory degenerative joint diseases, including osteoarthritis, post-traumatic arthritis, and vascular necrosis

  2. Rheumatoid arthritis

  3. Acute traumatic fracture of the femoral head or neck

  4. Certain cases of Ankylosis ï‚§ Dislocation of the hip

  5. Treatment of nonunion, femoral neck, and trochanteric fractures of the proximal femur

Hemi-hip arthroplasty is indicated in the following conditions:

  1. Acute traumatic fracture of the femoral head or neck that cannot be appropriately treated with internal fixation

  2. Fracture dislocation of the hip that cannot be appropriately treated with internal fixation.

  3. Avascular necrosis of femoral head

4.Certain high sub-capital and femoral neck fractures in the elderly.

  1. Degenerative arthritis involves only the femoral head, in which the acetabulum does not require replacement.

研究设计

研究类型
Observational

入排标准

年龄范围
11.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • Patients who were treated with the Libertas Hip Replacement System and will have completed a minimum of 2-year follow-up.

排除标准

  • As this is a retrospective review of data, there are no formal exclusion criteria for the study.

结局指标

主要结局

1. Mobility

时间窗: 1. Time frame: 24 months post-discharge | 2. Time Frame: through 24 | months | 3. Time frame: through 5 year, through 10 | year

2. Post-operative complications

时间窗: 1. Time frame: 24 months post-discharge | 2. Time Frame: through 24 | months | 3. Time frame: through 5 year, through 10 | year

3. Revision

时间窗: 1. Time frame: 24 months post-discharge | 2. Time Frame: through 24 | months | 3. Time frame: through 5 year, through 10 | year

次要结局

  • 1. Occurrence of surgical site complication(2. Swelling)

研究者

发起方
Meril Life Sciences Pvt Ltd
申办方类型
Other [Medical Device Company ]
责任方
Principal Investigator
主要研究者

Dr Kirankumar Shetty

Meril Life Sciences Pvt. Ltd

研究点 (3)

Loading locations...

相似试验

Hip Replacement System PMCF Study | 临床试验